Moderna, a biotechnology company specializing in mRNA therapeutics and vaccines, and IBM, a leading provider of global hybrid cloud and AI solutions, have announced a partnership to explore groundbreaking applications of quantum computing in mRNA science. Announced on April 20, 2023, the collaboration aims to accelerate and advance mRNA research with a focus on AI and quantum computing.
Quantum computing is an emerging technology that leverages the principles of quantum mechanics to solve problems too complex for classical computers. Moderna scientists will work with IBM to investigate the potential application of quantum approaches to their scientific challenges, participating in IBM’s Quantum Accelerator program and IBM Quantum Network. IBM will provide access to quantum computing systems and expertise to assist Moderna in exploring cutting-edge life sciences use-cases powered by quantum technologies.
Stéphane Bancel, Chief Executive Officer of Moderna, highlights the company’s commitment to being at the forefront of technology, stating that their partnership with IBM will develop novel AI models to advance mRNA science and prepare for the era of quantum computing. Dr. Darío Gil, Senior Vice President and Director of IBM Research, adds that IBM’s purpose of being a catalyst for a better world aligns perfectly with this partnership.
Another significant aspect of the collaboration involves the application of AI models for mRNA medicine design. Moderna and IBM scientists will use MoLFormer, an AI foundation model that can predict a molecule’s properties, to understand the characteristics of potential mRNA medicines. Moderna aims to optimize lipid nanoparticles and mRNA using MoLFormer. These particles encapsulate and protect mRNA as it travels within the body, instructing cells to combat diseases. Moderna and IBM will merge state-of-the-art formulation discovery with generative AI to design mRNA medicines with optimal safety and performance.
Over the past decade, Moderna has transformed from a research-stage company into an enterprise with a diverse clinical portfolio of vaccines and therapeutics. Their mRNA platform has enabled the development of treatments for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. With the authorized use and approval of one of the earliest and most effective COVID-19 vaccines, Moderna’s capabilities have demonstrated a significant global impact.
IBM serves clients in over 175 countries as a global leader in hybrid cloud, AI, and consulting expertise. Their breakthrough innovations in AI, quantum computing, industry-specific cloud solutions, and consulting provide open and flexible options to clients.
This partnership between Moderna and IBM represents a promising step toward harnessing the power of AI and quantum computing to revolutionize mRNA science, potentially leading to breakthroughs in mRNA medicine development and furthering the potential of this transformative technology in the healthcare industry.
